Glaucoma supplement trial halted early – no clear results

NCT ID NCT04784234

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a daily dietary supplement called GlaucoCetin could improve vision in people with open-angle glaucoma who already had some vision loss. Only 12 participants were enrolled before the trial was terminated early. The supplement contained a mix of ingredients thought to protect optic nerve cells, but because the study stopped, we don't have reliable data on whether it helped.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
GlaucoCetin (a dietary supplement containing curcumin, N-acetyl cysteine, ginkgo biloba, alpha-lipoic acid, citicoline, grape seed extract, green tea extract, coenzyme Q10, and other ingredients)
What this could lead to
If it had worked, GlaucoCetin might have pointed toward a way to slow vision loss in glaucoma by protecting optic nerve cells.
What could go wrong
The trial was terminated early with only 12 participants, so no reliable conclusions can be drawn. Dietary supplements often fail to show clear benefits in rigorous studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY OPEN ANGLE GLAUCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Wills Eye Hospital, Glaucoma Research Center

    Philadelphia, Pennsylvania, 19107, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.